ArticleAlcohol, clinical & experimental research2026
G9a inhibition reduces stress-potentiated alcohol drinking in both male and female mice: Implications for safe and effective pharmacological therapeutics for alcohol use disorder.
Article in Alcohol, clinical & experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlcohol use disorder (AUD) is a chronic, relapsing disease that is difficult to treat, and current therapies are not effective for many patients. Clinical studies show that stress increases heavy alcohol consumption and that stress is a predominant factor in rates of relapse. As such, pharmacotherapies that reduce stress-related alcohol drinking might be beneficial clinically. We recently showed that viral vector-mediated reduction of the epigenetic enzyme G9a (also known as euchromatic histone-lysine N-methyltransferase 2 or EHMT2) in the nucleus accumbens blocks stress-potentiated alcohol drinking. In addition, repeated systemic administration of the G9a inhibitor UNC0642 also reduces stress-potentiated alcohol drinking, suggesting that G9a inhibitors might be effective for treating AUD.
methodsHere, we further investigated the potential for UNC0642 to be used clinically to treat AUD. We first tested the effective dose of UNC0642 in multiple models of alcohol consumption in both male and female mice. We also tested half-life, oral bioavailability, maximum tolerated dose, and many measures of behavioral toxicity.
resultsWe found that UNC0642 is effective at reducing stress-potentiated alcohol consumption in both male and female mice at lower doses than we previously reported, and we re-confirmed the anxiolytic-like effects of UNC0642. We also found that UNC0642 has a long half-life in vivo, is orally bioavailable, is within an acceptable toxicity range for therapeutic use, and does not produce behavioral inhibition in many standard preclinical assessments, including locomotor activity, open field, Y-maze, rotarod, fear conditioning, sucrose self-administration, or sucrose-seeking.
conclusionsTogether, our studies suggest that G9a inhibitors could be effective, safe, and novel AUD therapeutics that reduce stress and dependence-related high levels of alcohol drinking in AUD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.